Oncology

Prestige BioPharma Plans Investment to Boost Its Drug Pipeline

May 22nd 2021

By Tony Hagen

Prestige BioPharma aims to expand its drug pipeline with a $152 million research and development facility.

Sandoz Panel Describes Issues, Opportunities for Biosimilars

May 21st 2021

By Tony Hagen

Biosimilar education can increase physician motivation to prescribe these alternatives to costly originator products, panelists said in a Sandoz/Reuters discussion.

AbbVie's Gonzalez Is on Defense as House Members Petition FTC

May 18th 2021

By Tony Hagen

Accused of unfair trade practices, AbbVie's CEO Richard Gonzalez pointed the finger at Medicare Part D.

Kaiser Permanente Investigators Confirm Mvasi Safety and Efficacy in Population With Nonsquamous NSCLC

May 18th 2021

The retrospective, real-world study (N = 353) conducted within the Kaiser Permanente network followed the July 2019 launch of the bevacizumab biosimilar Mvasi.

House Committee Issues Blistering Report on AbbVie's Humira Tactics

May 18th 2021

By Tony Hagen

The House Committee on Oversight and Reform contends AbbVie's "biosimilar defense strategy" has succeeded beyond the company's wildest imagination.

Study: Grastofil Equivalence Confirmed in ASCT Setting

May 14th 2021

By Deana Ferreri, PhD

A Canada study of the filgrastim biosimilar Grastofil demonstrated equivalence to Neupogen in candidates for autologous stem cell transplantation (ASCT), an extrapolated use.

Samsung Bioepis Executive Reflects on Interchangeable Designation

May 13th 2021

By Tony Hagen

A second class of biosimilars that are considered "interchangeable" could set biosimilars back in terms of acceptance, according to Albert Kim, MBA.

Coherus Aims to Chip Away at Onpro Dominance

May 12th 2021

By Tony Hagen

With COVID-19 on the retreat, Coherus BioSciences sees the advantage wearing off for Amgen's pegfilgrastim injector kit.

Not So Different: The Fight to Align Payer Preferences With Community Oncology

May 9th 2021

This is the third and final part of our series on National Comprehensive Cancer Network/Pfizer efforts to investigate issues of importance to biosimilar stakeholders.

Regulators Look Back on 15 Years of Biosimilars in Europe

May 7th 2021

By Tony Hagen

Advances in analytical testing have improved confidence in biosimilars, according to a Medicines for Europe panel.